Bear Bile Pill as add-on the Treatment of MDD

NCT04509882 | Unknown Phase 2

• 1 other identifier: NCTNCT04002259
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center. The purpose of this study is to determine the efficacy and safety of bear bile pill in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy. Following a screening period, subjects who meet the entry criteria will be randomized to treated with either placebo or 450mg bear bile pill three times daily for 8 weeks.

Conditions

Major Depressive Disorder

Outcome Measures

Primary Outcomes (1)

• Change in the total Montgomery-Asberg Depression Rating Scale (MADRS) score between randomization and end of study.

  The main objective is to explore whether bear bile pill add on SSRI or SNRI will improve the MDD symptoms after 8 weeks of treatment, and investigators assess the scale at baseline and week 1, 2, 4, 8.

  assessed from baseline to week 8(end of study)

Secondary Outcomes (7)

• Effective treatment

  assessed from baseline to week 8 (end of study)

• Clinical remission rate

  assessed from baseline to week 8 (end of study)

• The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio

  assessed from baseline to week 8 (end of study)

• The Hamilton Depression Rating Scale (HAM-D17) reduction ratio

  assessed from baseline to week 8 (end of study)

• change in the total score of the Hamilton Anxiety Scale(HAMA)

  assessed from baseline to week 8 (end of study)

Study Arms (2)

bear bile pill

EXPERIMENTAL

Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).

Drug: bear bile pill

placebo

PLACEBO COMPARATOR

Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).

Drug: placebo

Interventions

bear bile pill DRUG

Bear bile pill (15 pills) taken orally three times a day after meals with water.

bear bile pill

placebo DRUG

Placebo(15 pills) taken orally three times a day after meals with water.

placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Meets the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision (DSM-V) criteria for Major Depressive Disorder (MDD); a single or recurrent episode without psychotic features ;Codes are as follows: F32.0、F32.1、F32.2、F33.0、F33.1 、F33.2.
• Outpatients or inpatients.
• Male or female subjects aged 18-65 years.
• Patients have got standard treatment of SSRI/SNRI monotherapy for more than 4 weeks in current episode of depression before trial entry.
• MADRS score greater than 20.
• Women of childbearing potential must be willing to use acceptable methods of contraception throughout the study period and the following one month.
• The patient the patient fully understand and signed the informed consent form

You may not qualify if:

• Patient has survived a suicide attempt or has acute suicidal tendencies (MADRS Item 10 \> 4).
• Comorbidity according to DSM-V, axis I except major depressive disorder.
• Failed 3 or more adequate antidepressant courses in current episode of depression.
• MADRS reduction ratio ≥25% within one week from the screening to the baseline Visit.
• Depressive episode secondary to psychiatric illness or somatic disease.
• Serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases.
• History of alcohol or drug abuse over the last 6 months
• Allergic history to bear bile pills, or serious drug allergic history.
• Pregnant or lactating women and women of childbearing potential throughout the study period; men who have the desire of fertility within six months;
• Clinically significant changes in ECG or laboratory tests, including \>1.5X upper limit of normal liver function、over the limit of normal renal function and blood sugar、abnormal cardiac troponins、obvious abnormity in the thyroid function
• Treatment with MECT or rTMS in nearly three months.
• Treatment with a systematic psychological treatment in nearly three months.

Sponsors & Collaborators

• Shanghai Mental Health Center: lead

Study Sites (1)

Jing jing Huang

Shanghai, China

Location

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• Jingjing huang

  Shanghai Mental Health Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jing jing Huang

CONTACT

+86 021 34773308; jjhuang_att@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Shanghai Mental Health Center

Study Record Dates

• First Submitted: August 10, 2020
• First Posted: August 12, 2020
• Study Start: October 30, 2020
• Primary Completion: March 31, 2022
• Study Completion: March 31, 2022
• Last Updated: August 12, 2020

Record last verified: 2020-08

Locations

CN (1)